isosorbide dinitrate has been researched along with tirofiban in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chamorro, A; Díez-Marqués, ML; Griera, M; Rodríguez-Puyol, D; Rodríguez-Puyol, M; Ruiz-Torres, MP | 1 |
1 review(s) available for isosorbide dinitrate and tirofiban
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for isosorbide dinitrate and tirofiban
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Guanylate Cyclase; Humans; Hypertension; Isosorbide Dinitrate; Male; Muscle, Smooth, Vascular; Nitric Oxide Donors; Nitroprusside; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Tachyphylaxis; Time Factors; Tirofiban; Tyrosine; Up-Regulation; Vasodilation; Vasodilator Agents | 2009 |